Total Payments
$693,161
2024 Payments
$156,575
Companies
13
Transactions
373
Medicare Patients
1,514
Medicare Billing
$242,632
Payment Breakdown by Category
Research$247,809 (35.8%)
Consulting$231,720 (33.4%)
Other$159,309 (23.0%)
Travel$48,306 (7.0%)
Food & Beverage$3,760 (0.5%)
Education$2,256 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $247,809 | 36 | 35.8% |
| Consulting Fee | $231,720 | 57 | 33.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $154,009 | 68 | 22.2% |
| Travel and Lodging | $48,306 | 72 | 7.0% |
| Honoraria | $5,300 | 3 | 0.8% |
| Food and Beverage | $3,760 | 72 | 0.5% |
| Education | $2,256 | 65 | 0.3% |
Payments by Type
General
$445,351
337 transactions
Research
$247,809
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BIOVERATIV THERAPEUTICS INC. | $176,942 | 69 | $0 (2021) |
| GENZYME CORPORATION | $175,378 | 81 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $168,179 | 178 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $104,352 | 6 | $0 (2022) |
| ARGENX US, INC. | $26,762 | 24 | $0 (2024) |
| SANOFI US SERVICES INC. | $13,500 | 1 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $8,854 | 5 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $6,750 | 3 | $0 (2024) |
| RECORDATI_RARE_DISEASES_INC. | $5,513 | 1 | $0 (2024) |
| Janssen Global Services, LLC | $3,375 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156,575 | 57 | GENZYME CORPORATION ($66,390) |
| 2023 | $105,673 | 65 | GENZYME CORPORATION ($60,250) |
| 2022 | $125,967 | 34 | Rigel Pharmaceuticals, Inc. ($72,818) |
| 2021 | $45,502 | 12 | Rigel Pharmaceuticals, Inc. ($31,534) |
| 2020 | $37,611 | 29 | SANOFI US SERVICES INC. ($13,500) |
| 2019 | $45,573 | 52 | Alexion Pharmaceuticals, Inc. ($32,280) |
| 2018 | $141,824 | 14 | BIOVERATIV THERAPEUTICS INC. ($141,487) |
| 2017 | $34,436 | 110 | Alexion Pharmaceuticals, Inc. ($25,415) |
All Payment Transactions
373 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | RECORDATI_RARE_DISEASES_INC. | ENJAYMO (Drug) | Consulting Fee | Cash or cash equivalent | $5,512.50 | General |
| Category: HEMATOLOGY | ||||||
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $14,040.00 | General |
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $84.99 | General |
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $76.05 | General |
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $64.98 | General |
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $1,747.53 | General |
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $456.86 | General |
| 10/11/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,307.00 | General |
| Category: Hematology | ||||||
| 10/10/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 09/27/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 09/27/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,307.00 | General |
| Category: Hematology | ||||||
| 09/26/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,238.00 | General |
| Category: Hematology | ||||||
| 09/26/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Travel and Lodging | In-kind items and services | $337.68 | General |
| Category: Hematology | ||||||
| 09/26/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Travel and Lodging | In-kind items and services | $263.30 | General |
| Category: Hematology | ||||||
| 09/25/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $15,400.00 | General |
| Category: Immunology | ||||||
| 09/07/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $122.10 | General |
| Category: Immunology | ||||||
| 09/05/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $42.37 | General |
| Category: Immunology | ||||||
| 09/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $28.07 | General |
| Category: Immunology | ||||||
| 09/01/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $102.32 | General |
| Category: Immunology | ||||||
| 07/18/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| Category: Hematology | ||||||
| 07/18/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| Category: Hematology | ||||||
| 06/24/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 06/14/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Hematology | ||||||
| 06/14/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Hematology | ||||||
| 06/13/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $16,659.10 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Rigel Pharmaceuticals, Inc. | $72,818 | 4 |
| A PHASE 1 SAFETY, TOLERABILITY, AND PHARMACOKINETICS & PHARMACODYNAMICS OF MULTIPLE-DOSE BIVV009 in Patients with Chronic Immune Thrombocytopenia (ITP) | BIOVERATIV THERAPEUTICS INC. | $71,091 | 3 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | BIOVERATIV THERAPEUTICS INC. | $55,920 | 5 |
| C-935788-057 | Rigel Pharmaceuticals, Inc. | $31,534 | 2 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfu | BIOVERATIV THERAPEUTICS INC. | $7,200 | 1 |
| A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study) | GENZYME CORPORATION | $2,000 | 3 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP) | BIOVERATIV THERAPEUTICS INC. | $1,247 | 2 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | GENZYME CORPORATION | $1,000 | 2 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion | GENZYME CORPORATION | $1,000 | 3 |
| Long-term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia | BIOVERATIV THERAPEUTICS INC. | $918.00 | 2 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia | BIOVERATIV THERAPEUTICS INC. | $750.00 | 1 |
| A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)Cardinal Study | BIOVERATIV THERAPEUTICS INC. | $655.72 | 3 |
| A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study) | BIOVERATIV THERAPEUTICS INC. | $655.71 | 2 |
| Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-term Follow-up | BIOVERATIV THERAPEUTICS INC. | $623.34 | 2 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) | BIOVERATIV THERAPEUTICS INC. | $397.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 275 | 478 | $141,284 | $44,015 |
| 2022 | 6 | 333 | 608 | $172,435 | $57,791 |
| 2021 | 9 | 430 | 745 | $211,922 | $72,727 |
| 2020 | 10 | 476 | 874 | $218,168 | $68,099 |
Total Patients
1,514
Total Services
2,705
Medicare Billing
$242,632
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 152 | 325 | $82,916 | $24,318 | 29.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 48 | 70 | $24,306 | $8,592 | 35.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 42 | 42 | $20,554 | $6,537 | 31.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $9,713 | $3,088 | 31.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 21 | $3,795 | $1,480 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 159 | 330 | $82,830 | $26,434 | 31.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 61 | 96 | $32,448 | $11,292 | 34.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 41 | $19,905 | $7,041 | 35.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 55 | $13,750 | $4,954 | 36.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 28 | 28 | $13,468 | $4,559 | 33.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 58 | $10,034 | $3,512 | 35.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 153 | 322 | $80,822 | $25,238 | 31.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 112 | 172 | $58,136 | $20,891 | 35.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 51 | 51 | $24,786 | $9,188 | 37.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 82 | $20,500 | $7,695 | 37.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 25 | 25 | $12,080 | $4,165 | 34.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 51 | $8,823 | $3,332 | 37.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 15 | 15 | $3,900 | $1,463 | 37.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 13 | 16 | $1,456 | $473.44 | 32.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 11 | $1,419 | $281.96 | 19.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 106 | 263 | $66,085 | $16,889 | 25.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 63 | 73 | $35,471 | $13,116 | 37.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 45 | 170 | $29,410 | $10,727 | 36.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 112 | 161 | $21,024 | $6,610 | 31.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 50 | 69 | $23,337 | $6,436 | 27.6% |
About Dr. Catherine Broome, MD
Dr. Catherine Broome, MD is a Hematology & Oncology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669470985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Catherine Broome, MD has received a total of $693,161 in payments from pharmaceutical and medical device companies, with $156,575 received in 2024. These payments were reported across 373 transactions from 13 companies. The most common payment nature is "" ($247,809).
As a Medicare-enrolled provider, Broome has provided services to 1,514 Medicare beneficiaries, totaling 2,705 services with total Medicare billing of $242,632. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Washington, DC
- Active Since 07/11/2005
- Last Updated 03/31/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669470985
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $141,466
- Tavalisse (Drug) $104,352
- ENJAYMO (Biological) $53,178
- SOLIRIS (Drug) $42,348
- VYVGART (Drug) $26,762
- ULTOMIRIS (Biological) $24,938
- SUTIMLIMAB (Drug) $11,685
- SOLIRIS (Biological) $9,002
- ENJAYMO (Drug) $5,513
- Ultomiris (Drug) $4,175
- CABLIVI (Biological) $3,686
- Soliris (Drug) $2,150
- COLD AGGLUTININ DISEASE (Drug) $1,608
- Fabhalta (Drug) $1,013
- ULTOMIRIS (Drug) $813.89
- Eloctate (Drug) $102.02
- ELOCTATE (Drug) $20.62
- DARZALEX (Biological) $15.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Washington
Imad Tabbara, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
John Marshall
Hematology & Oncology — Payments: $770,250
Hematology & Oncology $770,250
Craig Kessler
Hematology & Oncology — Payments: $632,186
Hematology & Oncology $632,186
Claudine Isaacs
Hematology & Oncology — Payments: $406,847
Hematology & Oncology $406,847
Muhammad Mirza, M.d, M.D
Hematology & Oncology — Payments: $118,419
Hematology & Oncology $118,419
Dr. Christopher Gallagher, M.d, M.D
Hematology & Oncology — Payments: $107,252
Hematology & Oncology $107,252